Published in J Virol on September 01, 1990
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol (1992) 3.16
Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol (1993) 2.70
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol (1998) 2.00
CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol (1998) 1.95
CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol (1998) 1.85
Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest (1992) 1.81
Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.80
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66
Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol (1991) 1.62
Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol (1998) 1.52
Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J Virol (1997) 1.49
Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1. J Virol (1992) 1.36
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J Virol (1994) 1.15
Virus receptors: implications for pathogenesis and the design of antiviral agents. Clin Microbiol Rev (1995) 1.07
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol (2003) 1.06
Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 beta. Clin Exp Immunol (1995) 1.04
Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol (1999) 1.03
Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes. J Virol (1994) 0.98
Differential cell tropism of feline immunodeficiency virus molecular clones in vivo. J Virol (1999) 0.97
Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. Proc Natl Acad Sci U S A (1991) 0.95
Human immunodeficiency virus type 1 infection of the brain. Clin Microbiol Rev (1993) 0.94
HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) (2010) 0.94
Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology (2010) 0.85
CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo. J Virol (2013) 0.83
The productive entry pathway of HIV-1 in macrophages is dependent on endocytosis through lipid rafts containing CD4. PLoS One (2014) 0.83
Down regulation of CD4 expression following isolation and culture of human monocytes. Clin Diagn Lab Immunol (2000) 0.82
Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS. Front Microbiol (2015) 0.81
Protein kinase C and NF-κB-dependent CD4 downregulation in macrophages induced by T cell-derived soluble factors: consequences for HIV-1 infection. J Immunol (2011) 0.80
Proteomic-based identification of CD4-interacting proteins in human primary macrophages. PLoS One (2011) 0.79
Human retinal microglia express candidate receptors for HIV-1 infection. Br J Ophthalmol (2005) 0.78
Monocytes/macrophages in diagnosis and immunopathogenesis. Clin Diagn Lab Immunol (1999) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science (1986) 12.49
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol (1985) 7.35
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature (1987) 5.24
Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12
AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature (1987) 4.96
Pathogenesis of lentivirus infections. Nature (1986) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol (1983) 4.24
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature (1988) 4.15
The macrophage in the persistence and pathogenesis of HIV infection. AIDS (1989) 4.06
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res (1984) 3.67
Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature (1988) 3.63
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science (1988) 3.44
Epidermal Langerhans cells--a target for HTLV-III/LAV infection. J Invest Dermatol (1987) 3.41
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis. J Cell Biol (1988) 2.80
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Human T-cell lymphotropic virus type III infection of the central nervous system. A preliminary in situ analysis. JAMA (1986) 2.48
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (1989) 2.40
Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA (1986) 2.30
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology (1987) 2.30
Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol (1988) 2.22
Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature (1989) 2.17
Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology (1987) 2.11
Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocyte/macrophages. AIDS Res Hum Retroviruses (1987) 1.86
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol (1988) 1.79
Variations in CD4 expression by human monocytes and macrophages and their relationships to infection with the human immunodeficiency virus. J Gen Virol (1989) 1.72
Monoclonal antibodies that detect differentiation surface antigens on human myelomonocytic cells. Blood (1982) 1.57
Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature (1989) 1.55
Species heterogeneity in macrophage expression of the CD4 antigen. J Exp Med (1987) 1.49
HIV persistence in monocytes leads to pathogenesis and AIDS. Cell Immunol (1988) 1.37
Effect of polycations on sensitivity of BALD-3T3 cells to murine leukemia and sarcoma virus infectivity. Appl Microbiol (1971) 1.26
Organization of the middle RNA segment of snowshoe hare Bunyavirus. Virology (1988) 1.26
HIV infection of monocytic cells: rôle of antibody-mediated virus binding to Fc-gamma receptors. AIDS (1989) 1.24
Lentiviruses of animals are biological models of the human immunodeficiency viruses. Microb Pathog (1988) 1.01
Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages. J Infect Dis (1990) 0.90
Transformation of mammalian cells with genes from procaryotes and eucaryotes. Cell (1979) 21.15
Intragenic DNA spacers interrupt the ovalbumin gene. Proc Natl Acad Sci U S A (1978) 11.03
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Studies on lysosomes. XI. Characterization of a hydrolase-rich fraction from human lymphocytes. J Cell Biol (1968) 4.22
Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature (1972) 4.08
Altering genotype and phenotype by DNA-mediated gene transfer. Science (1980) 3.82
Human lymphocyte-sheep erythrocyte rosette formation: some characteristics of the interaction. Clin Immunol Immunopathol (1973) 3.55
Localization of A antigen sites on human erythrocyte ghosts. Nature (1971) 2.99
A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet (1990) 2.89
Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med (2001) 2.86
Purification of human monocytes on microexudate-coated surfaces. J Immunol (1978) 2.86
The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest (1978) 2.83
Prospective study of chlamydial infection in neonates. Lancet (1979) 2.80
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science (1991) 2.77
Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. II. Adoptive immunization of virus carriers. J Exp Med (1972) 2.68
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Studies on human peripheral blood lymphocytes in vitro. II. Morphological and biochemical studies on the transformation of lymphocytes by pokeweed mitogen. J Exp Med (1966) 2.63
Seasonality and the requirements for perpetuation and eradication of viruses in populations. Am J Epidemiol (1979) 2.58
The IgG receptor: an immunological marker for the characterization of mononuclear cells. Immunology (1969) 2.46
Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med (2010) 2.42
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
Sheep red cell binding to human lymphocytes treated with neuraminidase; enhancement of T cell binding and identification of a subpopulation of B cells. J Exp Med (1973) 2.37
Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol (1986) 2.37
Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. I. Cyclophosphamide-mediated induction by the virus-carrier state in adult mice. J Exp Med (1972) 2.37
Growth of Legionella pneumophila in thioglycolate-elicited peritoneal macrophages from A/J mice. Infect Immun (1988) 2.37
Studies on human peripheral blood lymphocytes in vitro. I. Biological and physicochemical properties of the pokeweed mitogen. J Exp Med (1966) 2.27
Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods (1986) 2.16
Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide. Nature (1968) 2.16
A 9 A resolution X-ray crystallographic map of the large ribosomal subunit. Cell (1998) 2.14
Chlamydia trachomatis: important relationships to race, contraception, lower genital tract infection, and Papanicolaou smear. J Pediatr (1984) 2.11
The importance of measuring cotinine levels to identify smokers in clinical trials. Clin Pharmacol Ther (1994) 2.11
Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol (1997) 2.08
A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene (2000) 2.07
Human lymphocyte response to phytomitogens in vitro: normal, agammaglobulinemic and paraproteinemic individuals. J Immunol (1969) 2.05
Studies on human peripheral blood lymphocytes in vitro. 3. Fine structural features of lymphocyte transformation by pokeweed mitogen. J Immunol (1967) 2.03
Direct localization and visualization of hyaluronate lyase activity by agar gel electrophoresis. Proc Soc Exp Biol Med (1967) 2.00
The genetics of susceptibility to multiple sclerosis. Epidemiol Rev (1982) 2.00
Gilles de la Tourette's syndrome: clinical, genetic, psychologic, and biochemical aspects in 21 selected families. Neurology (1977) 1.97
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A (1993) 1.96
There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys (1999) 1.96
Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. Lab Invest (1976) 1.96
Neurodevelopment and predictors of outcomes of children with birth weights of less than 1000 g: 1992-1995. Arch Pediatr Adolesc Med (2000) 1.95
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
Double-stranded RNA unwinding and modifying activity is detected ubiquitously in primary tissues and cell lines. Mol Cell Biol (1990) 1.89
The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol (1979) 1.87
Myasthenia gravis. Lancet (1966) 1.82
Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.80
Immunosuppression and experimental virus infection of the nervous system. Adv Virus Res (1970) 1.79
Human exposure to SV40: review and comment. Am J Epidemiol (1976) 1.77
Enhanced susceptibility of penicillin-resistant staphylococci to phagocytosis after in vitro incubation with low doses of nafcillin. Proc Soc Exp Biol Med (1974) 1.76
Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol (2001) 1.74
Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol (1988) 1.73
Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol (1988) 1.70
Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64 hours of sleep deprivation. J Clin Invest (1994) 1.70
Differences in HLA class II alleles of isolated South American Indian populations from Brazil and Argentina. Hum Immunol (1993) 1.69
Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med (2014) 1.68
Lymphocytic choriomeningitis virus: pathogenesis of acute central nervous system disease. Fed Proc (1972) 1.66
Modelling the impact of an influenza A/H1N1 pandemic on critical care demand from early pathogenicity data: the case for sentinel reporting. Anaesthesia (2009) 1.65
Protocol management of dysuria, urinary frequency, and vaginal discharge. Ann Intern Med (1974) 1.64
Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol (1986) 1.62
Fatal Japanese encephalitis virus infection in immunosuppresed spider monkeys. Clin Exp Immunol (1970) 1.61
Effects of RES "blockade" on antibody-formation. I. Suppressed cellular and humoral haemolysin responses in mice injected with carbon particles. Immunology (1969) 1.61
The effect of soft cervical collars on persistent neck pain in patients with whiplash injury. Acad Emerg Med (1996) 1.61
Radiometric detection of bacteremia: requirement for terminal subcultures. J Clin Microbiol (1977) 1.61
Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes. J Exp Med (1989) 1.60
Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol (1982) 1.60
A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr (1982) 1.60
Disappearance and recovery of human monocyte IgG receptor activity after phagocytosis. J Immunol (1972) 1.59
Marrow transplantation in chronic granulomatous disease: an update, with 6-year follow-up. J Pediatr (1988) 1.57
Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry (1999) 1.57
Regulated expression at high copy number allows production of a growth-inhibitory oncogene product in Drosophila Schneider cells. Genes Dev (1989) 1.56
Long-term human peripheral blood monocyte cultures: establishment, metabolism and morphology of primary human monocyte-macrophage cell cultures. Immunology (1979) 1.55
IgG subclass specificity of human monocyte receptor sites. Nature (1971) 1.55
Granulocytopathies: pleomorphism of neutrophil dysfunction. Am J Med (1969) 1.54
Electron microscopic and functional aspects of human lymphocyte response to mitogens. Transplant Rev (1972) 1.54
Bacterial heat shock proteins directly induce cytokine mRNA and interleukin-1 secretion in macrophage cultures. Infect Immun (1994) 1.54
Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest (1979) 1.54
Human lymphocytes express substance P and its receptor. J Neuroimmunol (1998) 1.52
Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis (1974) 1.51
Properties of retrovirus-like particles produced by a human breast carcinoma cell line: immunological relationship with mouse mammary tumor virus proteins. Proc Natl Acad Sci U S A (1984) 1.50
Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention. J Virol (1996) 1.50
Clinical, serologic and leukocyte function studies on patients with idiopathic "acquired" agammaglobulinemia and their families. Am J Med (1970) 1.50
Cryptococcal capsular polysaccharide-induced modulation of murine immune responses. Infect Immun (1982) 1.47
Lymphocytic choriomeningitis. Pathogenesis. Prog Med Virol (1974) 1.47
Staphylococcal IgE antibodies, hyperimmunoglobulinemia E and Staphylococcus aureus infections. N Engl J Med (1979) 1.47